ADORA2A and hepatocellular carcinoma: CD73 expression promoted mesenchymal phenotype in hepatocellular carcinoma and A2AR activation restored the effect of CD73 knockdown, suggesting an adjuvant treatment of CD73 and A2AR inhibitors (286).